Making earlier cancer detection a routine part of medical care

We're making earlier cancer detection a routine part of medical care to help eradicate the disease OUR TEAM 450 R&D team members 1,300 person commercial team 90 country presence EXACT SCIENCES OUR FLAGSHIP TESTS 960K people tested in 3Q22 cologuard® oncotype DXⓇ oncomap™ ExTra STRONG Q3 RESULTS Record revenue of $523M, 20% growth excluding COVID-19 testing Raising 2022 revenue guidance by $33M, decreasing OpEx guidance by $113M Accelerating adjusted EBITDA profitability to 3Q23 from 2024 3

View entire presentation